Dizal (Jiangsu) Pharmaceutical Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Zhang Xiaolin

Algemeen directeur

CN¥9.5m

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	1.8%
Management gemiddelde ambtstermijn	1.3yrs
Gemiddelde ambtstermijn bestuur	4.2yrs

Recente managementupdates

Recent updates

CEO

Zhang Xiaolin (60 yo)

no data

Tenure

CN¥9,534,800

Compensatie

Dr. Zhang Xiaolin Ph.D. is General Manager and Chairman of Dizal (Jiangsu) Pharmaceutical Co., Ltd. and served as its Chief Scientist. Dr. Xiaolin joined the Dizal (Jiangsu) Pharmaceutical Co., Ltd.in 201...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Zhang Xiaolin	GM & Chairman	no data	CN¥9.53m	1.76% CN¥ 329.7m
Lyu Hongbin	CFO & Board Secretary	4.8yrs	CN¥4.07m	geen gegevens
Zhiwei Zhang	Deputy GM	1.3yrs	CN¥1.81m	0.024% CN¥ 4.5m
Qingbei Zeng	Deputy GM	no data	CN¥2.03m	0.072% CN¥ 13.5m
Zhenfan Yang	Deputy GM & Chief Medical Officer	no data	CN¥3.59m	1.09% CN¥ 204.7m
Qingyi Wu	Deputy GM & Chief Commercial Officer	no data	CN¥5.23m	0.0028% CN¥ 532.4k
Honchung Tsui	Deputy GM	1.3yrs	CN¥2.31m	0.072% CN¥ 13.5m
Shih-Ying Chang	Deputy GM	no data	CN¥2.76m	0.0096% CN¥ 1.8m
Suqin Chen	Deputy GM & Senior VP of Clinical Operations	no data	CN¥2.98m	0.11% CN¥ 20.7m
Weijun Qiao	VP & Head of Registration Affairs	1.3yrs	CN¥1.98m	0.048% CN¥ 9.0m
Kan Chen	Vice President of Clinical Pharmacology	no data	CN¥1.72m	0.0072% CN¥ 1.4m
Xiaojing Kang	Employee Supervisor & Head of Accounting Agency	no data	geen gegevens	0.0041% CN¥ 766.7k

1.3yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 688192 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Zhang Xiaolin	GM & Chairman	no data	CN¥9.53m	1.76% CN¥ 329.7m
Xiaojing Kang	Employee Supervisor & Head of Accounting Agency	2.8yrs	geen gegevens	0.0041% CN¥ 766.7k
Guanshan Zhu	Independent Director	4.2yrs	CN¥100.00k	geen gegevens
Simon Dazhong Lu	Director	7.8yrs	geen gegevens	geen gegevens
Rodolphe Peter Andre Grepinet	Director	7.8yrs	geen gegevens	geen gegevens
Jiang Bin	Independent Director	4.2yrs	CN¥100.00k	geen gegevens
Wang Xuegong	Independent Director	4.2yrs	CN¥100.00k	geen gegevens
Zhang Xin	Independent Director	4.2yrs	CN¥100.00k	geen gegevens
Dong Weiwen	Chairman of the Supervisory Board	no data	geen gegevens	geen gegevens
Yuan Sun	Supervisor	no data	geen gegevens	geen gegevens

4.2yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 688192 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).

Dizal (Jiangsu) Pharmaceutical Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Dizal (Jiangsu) Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

Insufficient new directors

Less than half of directors are independent

Recent updates

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Dizal Receives Breakthrough Therapy Designation by China CDE for the First-Line Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

NMPA Approves Burning Rock and Dizal's First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer in China

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Dizal Announces the National Medical Products Administration of China Approves Golidocitinib for the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

New minor risk - Share price stability

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Presents Latest Data from the Inaugural Global Pivotal Study WU-KONG1 Part B (WU-KONG1B) of Sunvozertinib in Relapsed or Refractory Non-Small Cell Lung Cancer

Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

New major risk - Financial position

Dizal (Jiangsu) Pharmaceutical Co., Ltd., Annual General Meeting, May 21, 2024

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces Two Abstracts Featuring the Latest Data on Sunvozertinib in Non-Small Cell Lung Cancer

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Dizal's Sunvozertinib for the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

New major risk - Revenue and earnings growth

Now 21% undervalued

Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine

Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH

New major risk - Share price stability

Dizal Announces Latest Research Findings on the Efficacy and Safety of Sunvozertinib in Treatment-Naive Patients

Insufficient new directors

Dizal Pharmaceutical Receives Priority Review by China NMPA for the Treatment of r/r PTCL

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL

Dizal Pharmaceutical Announces Clinical Results of Golidocitinib Published in Annals of Oncology

New major risk - Revenue and earnings growth

Dizal Will Present the Results of Molecular Analysis on EGFR Exon20ins Mutations in Tumor Tissue and Plasma ctDNA

Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Presents Compelling Data of Its Robust Oncology Portfolio At the 2023 American Society of Clinical Oncology Annual Meeting

Less than half of directors are independent

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd